scispace - formally typeset
Journal ArticleDOI

Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.

Reads0
Chats0
TLDR
Humoral rejection is a clinicopathologic entity with a high incidence in women and is associated with acute hemodynamic compromise, accelerated transplant coronary artery disease and death.
Abstract
Background Acute cellular rejection is the mechanism of most immune-related injury in cardiac transplant recipients. However, antibody-mediated humoral rejection (HR) has also been implicated as an important clinical entity following orthotopic heart transplantation. Humoral rejection has been reported to play a role in graft dysfunction in the early post-transplant period, and to be a risk factor for the development of transplant coronary artery disease. Some involved in transplantation pathology doubt the existence of clinically significant humoral rejection in cardiac allografts. Those who recognize its existence disagree on its possible role in graft dysfunction or graft coronary artery disease. In this study, we report clinical features of patients with the pathologic diagnosis of HR at our institution since July 1997, when we began systematic surveillance for humoral rejection. Methods We reviewed medical records of patients with the pathologic diagnosis of HR without concurrent cellular rejection between July 1997 and January 2001. Diagnosis was based on routine histology (“swollen cells” distending capillaries, interstitial edema and hemorrhage) and immunofluorescence (capillary deposition of immunoglobulin and complement with HLA-DR positivity), or immunoperoxidase staining of paraffin-embedded tissue (numerous CD68-positive macrophages and fewer swollen endothelial cells distending capillaries). Results A total of 44 patients (4 to 74 years old) showed evidence of HR without concurrent cellular rejection at autopsy or on one or more biopsies. Although females comprised only 26% of our transplant population, 23 patients (52%) with HR were female. A positive peri-operative flow cytometry T-cell crossmatch was observed in 32% of HR patients compared with 12% of controls ( p = 0.02). Hemodynamic compromise consisting of shock, hypotension, decreased cardiac output/index and/or a rise in capillary wedge or pulmonary artery pressure was observed in 47% of patients at the time of diagnosis of HR. Six patients (5 females) died (14% mortality) with evidence of HR at or just before autopsy, 6 days to 16 months after transplantation. The incidence of transplant coronary artery disease was 10% greater at 1 year, and 36% greater at 5 years, in patients with HR when compared with non-HR patients. Conclusion Humoral rejection was associated with acute hemodynamic compromise in 47% of patients, and was the direct cause of death in 6 patients (13%). Humoral rejection is a clinicopathologic entity with a high incidence in women and is associated with acute hemodynamic compromise, accelerated transplant coronary artery disease and death.

read more

Citations
More filters
Journal ArticleDOI

Antibody-mediated Rejection in Heart Transplantation

TL;DR: Heart transplantation is an excellent long-term treatment that confers functionality and longevity in select patients with end-stage heart failure, yet, allograft rejection continues to pose a significant threat, especially in high-risk recipients and soon after transplantation.
Journal ArticleDOI

Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.

TL;DR: Children who develop AMR have worse cardiovascular outcome than recipients who develop only ACR or experience no rejection at all, according to a retrospective single‐center study of 104 HTx recipients.
Journal ArticleDOI

C4d-the witness of humoral rejection.

TL;DR: C4d positivity is a morphologic sign of humoral rejection that may hasten the appearance and/or worsening of allograft vasculopathy independent of patient age or posttransplantation time.
Journal ArticleDOI

Management of Patients With Preformed Reactive Antibodies Who Are Awaiting Cardiac Transplantation

TL;DR: Options for managing patients with preformed antibodies and a case report are presented and a variety of treatments are used in cardiac transplantation programs in attempts to reduce the concentration of preformed reactive antibodies.
Journal ArticleDOI

Severe cardiac allograft dysfunction without endomyocardial biopsy signs of cellular rejection: incidence and management.

TL;DR: Twelve patients with acute dysfunction of cardiac allograft without evidence of cellular rejection among 438 heart transplants displayed this condition were treated with methylprednisolone "bolus" and plasmapheresis until clinical recovery, after which their immunosuppressive regimens were modified.
References
More filters
Journal ArticleDOI

Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and Atherosclerosis

TL;DR: It is demonstrated that CMV infection in cardiac transplant recipients is associated with more frequent rejection, graft atherosclerosis, and death.
Journal ArticleDOI

Transplantation of discordant xenografts: a review of progress.

TL;DR: In this paper, a model of hyperacute rejection was proposed and it was shown that if hyper-accurate rejection can be averted for a period after transplantation, prolonged xenograft survival is possible.
Journal ArticleDOI

Immunopathology of hyperacute xenograft rejection in a swine-to-primate model.

TL;DR: It is suggested that rhesus IgM contributes significantly to the development of hyperacute rejection in the swine to Rhesus model and that the fixation of complement is a critical factor in the recruitment of the coagulation cascade and platelet aggregation--and possibly in the adherence and infiltration of PMN.
Journal Article

Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications.

TL;DR: It is concluded that immunofluorescence should be routinely done on all heart biopsies for the first month after transplantation, because patients with vascular (humoral) rejection cannot be reliably identified by any other means.
Journal ArticleDOI

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

TL;DR: I.v.IG appears to be an effective therapy to control posttransplant AR episodes in heart and kidney transplant recipients, including patients who have had no success with conventional therapies.
Related Papers (5)